Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Bioavailability of Verducatib in Healthy Volunteers
NCT06166992Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of verducatib in bronchiectasis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity up to 10 days. Started Dec 2023; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06166992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06166992.